Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT01165632
Other study ID # MC1078
Secondary ID NCI-2010-0160710
Status Active, not recruiting
Phase Early Phase 1
First received
Last updated
Start date July 26, 2010
Est. completion date December 30, 2024

Study information

Verified date September 2023
Source Mayo Clinic
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

RATIONALE: New imaging procedures, such as fluorine F 18 fluorodopa-labeled PET scan, may help in guiding surgery and radiation therapy and allow doctors to plan better treatment. PURPOSE: This clinical trial studies fluorine F 18 fluorodopa-labeled PET scan in planning surgery and radiation therapy in treating patients with newly diagnosed high- or low-grade malignant glioma


Description:

PRIMARY OBJECTIVES: I. To determine correlation between 18F-FDOPA PET activity, MRI contrast enhancement, and high- or low-grade glioma biopsies. II. To compare radiotherapy target volume delineation with and without 18F- FDOPA-PET metabolic imaging information to determine role of metabolic imaging in radiotherapy treatment planning. SECONDARY OBJECTIVES: I. To determine correlation between concordance of 18F-FDOPA PET activity, MRI contrast enhancement, and high- or low-grade glioma biopsies and patient outcomes including overall survival and progression free survival. OUTLINE: Beginning at no more than 1 week before biopsy and resection, patients undergo fluorine F 18 fluorodopa-labeled PET/CT scan and pre-operative MRI. Patients then undergo stereotactic craniotomy. Some patients may also undergo radiation therapy. After completion of study treatment, patients are followed up every year for 5 years.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 24
Est. completion date December 30, 2024
Est. primary completion date November 1, 2013
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Age =18 years. - MRI findings compatible with newly diagnosed high- or low-grade malignant glioma - Planned craniotomy and resection or biopsy - Willing to sign release of information for any radiation and/or follow-up records - Negative pregnancy test done =< 48 hours of injection of study drug, for women of childbearing potential only - Provide informed written consent - Patients with eGFR < 60 mg/min/1.72m2 are eligible for the study; PLEASE NOTE: the patient is not eligible to receive the contrast for the pMRI at the study dose. Exclusion Criteria: - Unable to undergo MRI scans with contrast (e.g. cardiac pacemaker, defibrillator, kidney failure) - Unable to undergo an 18F-FDOPA PET scan (e.g. Parkinson's Disease, taking anti-dopaminergic, or dopamine agonist medication or less than 6 half-lives from discontinuance of dopamine agonists) - Pregnant women; nursing women; men or women of childbearing potential who are unwilling to employ adequate contraception

Study Design


Related Conditions & MeSH terms

  • Adult Anaplastic Astrocytoma
  • Adult Anaplastic Ependymoma
  • Adult Anaplastic Oligodendroglioma
  • Adult Brain Stem Glioma
  • Adult Diffuse Astrocytoma
  • Adult Ependymoma
  • Adult Giant Cell Glioblastoma
  • Adult Glioblastoma
  • Adult Gliosarcoma
  • Adult Mixed Glioma
  • Adult Myxopapillary Ependymoma
  • Adult Oligodendroglioma
  • Adult Pilocytic Astrocytoma
  • Adult Pineal Gland Astrocytoma
  • Adult Subependymal Giant Cell Astrocytoma
  • Adult Subependymoma
  • Astrocytoma
  • Ependymoma
  • Glioblastoma
  • Glioma
  • Gliosarcoma
  • Oligodendroglioma

Intervention

Procedure:
biopsy
Correlative studies
computed tomography
Undergo computed tomography
therapeutic conventional surgery
Undergo stereotactic craniotomy
Radiation:
radiation therapy treatment planning/simulation
Undergo radiation therapy treatment planning/simulation
radiation therapy
Undergo radiation therapy
Procedure:
magnetic resonance imaging
Undergo magnetic resonance imaging
positron emission tomography
Undergo positron emission tomography
Drug:
fluorine F 18 fluorodopa
Given IV

Locations

Country Name City State
United States Mayo Clinic Rochester Minnesota

Sponsors (2)

Lead Sponsor Collaborator
Mayo Clinic National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary 18F-FDOPA PET activity, MRI contrast enhancement, and high- or low-grade glioma biopsies Determine correlation between 18F-FDOPA PET activity, MRI contrast enhancement, and high- or low-grade glioma biopsies. Up to 2 years
Primary 18F- FDOPA-PET metabolic imaging information Compare radiotherapy target volume delineation with and without 18F- FDOPA-PET metabolic imaging information to determine role of metabolic imaging in radiotherapy treatment planning. Up to 2 years
Secondary Concordance of 18F-FDOPA PET and 11C-choline activity, MRI contrast enhancement, and high- or low-grade glioma biopsies Determine correlation between concordance of 18F-FDOPA PET and 11C-choline activity, MRI contrast enhancement, and high- or low-grade glioma biopsies and patient outcomes including overall survival and progression free survival. Up to 2 years
Secondary With and without 18F- FDOPA PET, 11C-choline PET metabolic imaging information Compare radiotherapy target volume delineation with and without 18F- FDOPA PET, 11C-choline PET metabolic imaging information; pMRI and DTI advanced MR imaging, to determine role in radiotherapy treatment planning. 2 Years
Secondary 18F-FDOPA PET activity, 11C-choline PET activity, MRI contrast enhancement, pMRI, and DTI, with high- or low-grade glioma biopsies Determine correlation between 18F-FDOPA PET activity, 11C-choline PET activity, MRI contrast enhancement, pMRI, and DTI, with high- or low-grade glioma biopsies. 2 years
See also
  Status Clinical Trial Phase
Terminated NCT02530502 - Radiation Therapy With Temozolomide and Pembrolizumab in Treating Patients With Newly Diagnosed Glioblastoma Phase 1
Withdrawn NCT02194452 - Efficacy of 68Ga-DOTATOC Positron Emission Tomography (PET) CT in Children and Young Adults With Brain Tumors N/A
Completed NCT00238303 - Vorinostat in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme Phase 2
Completed NCT00049387 - Tipifarnib, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma Phase 1
Completed NCT02227901 - Tipifarnib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Phase 1
Completed NCT02015819 - Genetically Modified Neural Stem Cells, Flucytosine, and Leucovorin for Treating Patients With Recurrent High-Grade Gliomas Phase 1
Active, not recruiting NCT02179086 - Dose-Escalated Photon IMRT or Proton Beam Radiation Therapy Versus Standard-Dose Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Phase 2
Recruiting NCT04573140 - A Study of RNA-lipid Particle (RNA-LP) Vaccines for Newly Diagnosed Pediatric High-Grade Gliomas (pHGG) and Adult Glioblastoma (GBM) Phase 1
Active, not recruiting NCT00823797 - Bendamustine Hydrochloride in Treating Patients With Recurrent or Progressive Anaplastic Glioma Phase 2
Completed NCT00045565 - Arsenic Trioxide Plus Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma Phase 1
Completed NCT01977677 - Plerixafor After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed High Grade Glioma Phase 1/Phase 2
Completed NCT01648348 - Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme Phase 1/Phase 2
Completed NCT00004262 - Radiation Therapy and Gadolinium Texaphyrin in Treating Patients With Supratentorial Glioblastoma Multiforme Phase 1
Terminated NCT01996527 - 3T MRI Biomarkers of Glioma Treatment Response Early Phase 1
Terminated NCT01575275 - Aminolevulinic Acid in Visualizing a Tumor During Surgery in Patients With Glioblastoma Multiforme Phase 2
Completed NCT01119599 - RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma Phase 1
Terminated NCT01103375 - Erlotinib Hydrochloride and Isotretinoin in Treating Patients With Recurrent Malignant Glioma Phase 1
Completed NCT01131234 - Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors Phase 1
Completed NCT00459381 - Pazopanib in Treating Patients With Recurrent Glioblastoma Phase 2
Completed NCT00316849 - Temsirolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Phase 1